Compare EML & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | TLSI |
|---|---|---|
| Founded | 1858 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 270.2M |
| IPO Year | 1995 | 2020 |
| Metric | EML | TLSI |
|---|---|---|
| Price | $24.91 | $4.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 9.6K | ★ 95.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $248,970,345.00 | $45,151,000.00 |
| Revenue This Year | $19.05 | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $23.95 | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $17.61 | $2.20 |
| 52 Week High | $29.91 | $7.95 |
| Indicator | EML | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 48.60 |
| Support Level | $24.10 | $4.70 |
| Resistance Level | $27.16 | $5.58 |
| Average True Range (ATR) | 1.36 | 0.28 |
| MACD | -0.25 | -0.02 |
| Stochastic Oscillator | 16.23 | 43.33 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.